Related Experiment Video
Updated: Jul 14, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Allosteric enhancers for A1 adenosine receptor.
Pier Giovanni Baraldi1, Maria Antonietta Iaconinoto, Allan R Moorman
1Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Ferrara, Italy. baraldi@unife.it
Allosteric enhancers targeting the adenosine A(1) receptor show promise for treating cardiac arrhythmias and reducing fat breakdown. These compounds also offer potential as pain relievers and neuroprotective agents.
Area of Science:
- Pharmacology
- Neuroscience
- Cardiology
Background:
- Adenosine A(1) receptor allosteric modulators are investigated for diverse therapeutic applications.
- Previous research highlighted their roles in cardiac function and lipolysis.
- Potential in pain management and neuroprotection is also recognized.
Purpose of the Study:
- To explore the therapeutic potential of allosteric enhancers at the adenosine A(1) receptor.
- To focus on compounds with enhanced efficacy and reduced antagonist activity.
Main Methods:
- Literature review of studies on adenosine A(1) receptor allosteric modulators.
- Analysis of structure-activity relationships for enhancer compounds.
- Evaluation of preclinical and clinical data on therapeutic applications.
Main Results:
- Allosteric enhancers demonstrate efficacy as anti-arrhythmic agents.
- These compounds show potential as anti-lipolytic agents.
- Therapeutic benefits for analgesia and neuroprotection were identified.
Conclusions:
- Adenosine A(1) receptor allosteric enhancers represent a promising class of drugs.
- Compounds with improved enhancer potency and diminished antagonist properties are of particular interest.
- Further research is warranted to fully elucidate their therapeutic applications.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Related Concept Videos
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...